The Staploe Medical Centre
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gunstone, Anthony
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

Recruiting
3
412
Europe, Canada, US, RoW
Salbutamol HFA-134a, Salbutamol HFA-152a
GlaxoSmithKline
Asthma
04/25
04/25
NCT06551181: A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

Recruiting
3
2600
Europe, Japan, RoW
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/25
09/25
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27

Download Options